Form 4: AVTX Director Sells Shares After Option Exercise
Insider Transaction Report
Avalo Therapeutics Director Jonathan Goldman reported exercising stock options and subsequently selling common stock on November 14, 2025.
Summary
- Jonathan Goldman, a Director of Avalo Therapeutics, Inc. (AVTX), engaged in transactions involving the company's common stock and stock options.
- On November 14, 2025, Goldman exercised 8,200 stock options at an exercise price of $9.88 per share.
- Immediately following the exercise, Goldman sold 8,200 shares of common stock at an average price of $14.3474 per share, with prices ranging from $14.02 to $14.60.
- Additionally, 3,167 shares of common stock were sold at a price of $14.30 per share.
- Following these reported transactions, Goldman beneficially owns 0 shares of common stock directly.
- Goldman continues to beneficially own 16,400 derivative securities in the form of stock options.
Sentiment
Score: 5
Explanation: Neutral, as this Form 4 reports factual insider transactions. The director profited from the sale, but the transaction itself does not inherently indicate a positive or negative outlook for the company.
Positives
- The director realized a profit from the exercise of stock options and subsequent sale of common stock, as the sale price ($14.3474 average) was higher than the exercise price ($9.88).
Negatives
- The director reduced direct equity exposure by selling all shares acquired through the option exercise, along with additional shares.
Future Outlook
No specific future outlook or guidance is provided in this insider transaction report.
Industry Context
This filing is a standard insider transaction report and does not provide broader industry context or trends.
Related Party Transactions
- Jonathan Goldman, a Director of Avalo Therapeutics, Inc., engaged in transactions involving the exercise of stock options and the sale of common stock.
Stakeholder Impact
- Shareholders may view the director's sale of shares as a routine monetization of options, which is common, but it also represents a reduction in direct insider ownership.
Next Steps
- Remaining stock options held by the director are scheduled to vest 1/3 on March 28, 2026, and March 28, 2027, contingent on continued service.
Key Dates
| Date | Description |
|---|---|
| 03/28/2025 | First vesting date for 1/3 of the stock options, subject to continued service. |
| 03/28/2026 | Second vesting date for 1/3 of the stock options, subject to continued service. |
| 03/28/2027 | Third vesting date for 1/3 of the stock options, subject to continued service. |
| 11/14/2025 | Date of stock option exercise and common stock sales by the reporting person. |
| 11/17/2025 | Date the Form 4 filing was signed. |
| 08/13/2034 | Expiration date of the stock options. |
Keywords
Avalo Therapeutics, AVTX, Form 4, Insider Trading, Stock Option Exercise, Common Stock Sale, Director Transaction, Jonathan Goldman
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.